Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Source: aol.com
📰 David Ricks News
Page 7 - David Ricks News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from David Ricks. Real-time updates on events, politics, business and more.
Patients on hunt for diabetes, obesity and weight-loss drugs – Indianapolis Business Journal
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
Source: ibj.com
Eli Lilly soars 8% after Q1 earnings reveal surging popularity for its Zepbound weight-loss drug
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's conference call.
Source: yahoo.com
Eli Lilly Stock Rises: Q1 Earnings Show Demand for Zepbound Weight-Loss Drug
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's conference call.
Source: businessinsider.com
Demand for weight-loss drug drives Eli Lilly to raise 2024 sales forecast by US$2-billion
Eli Lilly said it expects significant production increases in the second half of the year for its obesity treatment and related diabetes drug Mounjaro
Source: theglobeandmail.com
Eli Lilly (LLY) earnings Q1 2024
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Source: cnbc.com
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound drugs soar
Shares of world’s most valuable pharmaceuticals group reapproach record highs
Source: irishtimes.com
Market movers: Stocks seeing action on Tuesday - and why
A look at North American equities heading in both directions
Source: theglobeandmail.com
Lilly sees quarterly profit jump 67% on demand for new weight-loss drugs – Indianapolis Business Journal
Doctors and pharmacies have reported huge demand for Mounjaro and Zepbound in recent months, causing widespread shortages of the popular drugs.
Source: ibj.com